ASLAN003 gets Orphan Drug Designation for AML

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Aslan Pharmaceuticals said FDA has granted ASLAN003 Orphan Drug Designation as a treatment for acute myeloid leukemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Young adults with cancer are starting to break the silence about grief. Most people think of grief following the death of a loved one, but grief can accompany any event that disrupts or challenges our sense of normalcy or ourselves. During this first week of December, National Grief Awareness Week, we can raise awareness about grief in young adults with cancer to help ensure that no one grieves alone. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login